title: Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit weight maintenance for diabetic patients. We performed a systematic review to evaluate its weight loss effect on obese/overweight patients without diabetes in randomized controlled trials (RCTs).
  
  
  METHODS
  Literature updated to May 5, 2014 from Cochrane Library, MEDLINE, EMBASE and reference lists from relevant articles were identified. RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed. Studies lacking primary measurements were excluded. Three authors extracted data independently. Either fixed-effect or random-effect models were used to calculate weighted mean differences (WMDs), combined relative risks (RR) and 95% confidence interval (CI) in meta-analyses. Intertrial heterogeneity across studies was examined by I(2) and Q statistics.
  
  
  RESULTS
  A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks. Participants in GLP-1RA groups achieved a larger weight loss than those in control groups (-2.85 kg, 95%CI -3.55 to -2.14), and liraglutide may work in a dose-dependent fashion. GLP-1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation. But GLP-1RAs were associated with increased nausea and vomiting events.
  
  
  CONCLUSIONS
  GLP-1 mimetics induce a weight loss in addition to BMI and WC reduction in obese/overweight adults without diabetes. Further long-term randomized trials and basic studies are required to investigate the mechanisms.
authors.affiliation: Division of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Zhang
authors.forename: Yuzhen
authors.initials: Y
authors.lastname: Tong
authors.forename: Na
authors.initials: N
authors.lastname: Su
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Lizhi
authors.initials: L
authors.lastname: Tang
authors.forename: Li
authors.initials: L
authors.lastname: Huang
authors.forename: Nanwei
authors.initials: N
authors.lastname: Tong
mesh_terms: D000328:Adult; D032701:Biomimetics; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*; D050177:Overweight / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D018027:Receptors, Glucagon / Q000819:agonists*; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D007004:Hypoglycemic Agents; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1
keywords: glucagon-like peptide-1 mimetics; meta-analysis; non-diabetes; obesity; weight loss; 关键词：胰高血糖素样肽-1类似物，meta分析，非糖尿病，肥胖，减重。